Regulus Therapeutics Inc. nailed down a deal with GlaxoSmithKline plc to develop an miR-122 antagonist in hepatitis C virus in a $150 million-plus partnership that cast a spotlight on intellectual property rights relating to the liver-specific microRNA target, given that GSK previously declined an option for a clinical-stage drug from Danish firm Santaris Pharma A/S. (BioWorld Today) Read More
